Osteoporosis Trial, Recruiting NCT05571514 Sponsor: Centre Hospitalier Universitaire de Saint Etienne Condition: Osteoporosis
Back to Osteoporosis

Osteoporosis Trial, Recruiting

NCT05571514
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women who have gone through menopause and are between 50 and 65 years old
  • People whose bone density scan results fall in a range that suggests lower than normal bone density but not yet full osteoporosis (a T-score between -1 and -3)
  • People who have not had any broken bones caused by weak or fragile bones in the past

Who may not be able to join:

  • People who do not have parathyroid glands, which are small glands that help the body control calcium and phosphorus levels (confirm with trial site)
  • People who have or have had kidney stones
  • People who are currently taking medications that can affect bone health, such as corticosteroids, menopausal hormone therapy, anti-oestrogen treatments, or those with an uncontrolled thyroid condition or a thyroid that is either overactive or underactive
  • People who have a bone disease such as Paget's disease or osteomalacia (a condition where bones soften due to vitamin D or mineral problems)
  • People with chronic alcohol dependency

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Adamah AMOUZOUGAN, MD, Centre Hospitalier Universitaire de Saint Etienne

Phone: (0)477120595

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Registry
ClinicalTrials.gov
Start date
12 May 2023
Est. completion
1 November 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Change in bone loss at lumbar site

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov